Tag «Phase II»

Reldesemtiv

It’s only fair to share… Reldesemtiv CK-2127107 CAS 1345410-31-2 UNII-4S0HBYW6QE, 4S0HBYW6QE MW 384.4 g/mol, MF C19H18F2N6O 1-[2-({[trans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methyl}amino)pyrimidin-5-yl]-1H-pyrrole-3- carboxamide 1-[2-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyrimidin-5-yl]pyrrole-3-carboxamide Reldesemtiv, also known as CK-2127107, is a skeletal muscle troponin activator (FSTA) and is a potential treatment for people living with debilitating diseases and conditions associated with neuromuscular or non-neuromuscular dysfunction, muscular weakness, and/or muscle fatigue such as SMA, …

Ceralasertib, AZD 6738

It’s only fair to share… AZD-6738, Ceralasertib Molecular Formula C20H24N6O2S Average mass 412.509 Da CAS 1352226-88-0 [RN] 1H-Pyrrolo[2,3-c]pyridine, 4-[4-[(3R)-3-methyl-4-morpholinyl]-6-[1-(S-methylsulfonimidoyl)cyclopropyl]-2-pyrimidinyl]- 4-{4-[(3R)-3-Methyl-4-morpholinyl]-6-[1-(S-methylsulfonimidoyl)cyclopropyl]-2-pyrimidinyl}-1H-pyrrolo[2,3-c]pyridine 1H-Pyrrolo(2,3-b)pyridine, 4-(4-(1-((S(R))-S-methylsulfonimidoyl)cyclopropyl)-6-((3R)-3-methyl-4-morpholinyl)-2-pyrimidinyl)- imino-methyl-[1-[6-[(3R)-3-methylmorpholin-4-yl]-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-λ6-sulfane 85RE35306Z AZD-6738 UNII:85RE35306Z CAS : 1352226-88-0 (free base)   1352280-98-8 (formic acid)   1352226-97-1 (racemic) 4-[4-[1-[[S(R)]-S-Methylsulfonimidoyl]cyclopropyl]-6-[(3R)-3-methyl-4-morpholinyl]-2-pyrimidinyl]-1H-pyrrolo[2,3-b]pyridine AZD 6738 Ceralasertib Originator AstraZeneca; University of Pennsylvania Class Antineoplastics; Morpholines; Pyrimidines; Small molecules Mechanism of Action ATR protein inhibitors Phase II Breast cancer; Gastric cancer; Non-small cell …

SEVITERONEL, севитеронел , سيفيتيرونيل , 赛维罗奈 ,

It’s only fair to share… SEVITERONEL CAS Registry Number 1610537-15-9 Molecular formulaC18 H17 F4 N3 O3, MW 399.34 1H-1,2,3-Triazole-5-methanol, α-[6,7-bis(difluoromethoxy)-2-naphthalenyl]-α-(1-methylethyl)-, (αS)- (αS)-α-[6,7-Bis(difluoromethoxy)-2-naphthalenyl]-α-(1-methylethyl)-1H-1,2,3-triazole-5-methanol 8S5OIN36X4 севитеронел [Russian] [INN] سيفيتيرونيل [Arabic] [INN] 赛维罗奈 [Chinese] [INN] Mechanism of ActionAndrogen receptor antagonists; Estrogen receptor antagonists; Steroid 17-alpha-hydroxylase inhibitors; Steroid 17-alpha-hydroxylase modulators WHO ATC codeL01 (Antineoplastic Agents)L01X-X (Other antineoplastic agents) EPhMRA codeL1 (Antineoplastics)L1X9 (All other antineoplastics) 1H-1,2,3-Triazole-5-methanol, alpha-(6,7-bis(difluoromethoxy)-2-naphthalenyl)-alpha-(1-methylethyl)-, (alphaS)- …

OLACAFTOR, VX 440

It’s only fair to share… OLACAFTOR, VX 440 CAS 1897384-89-2 Molecular Formula: C29H34FN3O4S Molecular Weight: 539.666 g/mol CFTR corrector; UNII-RZ7027HK8F; RZ7027HK8F; Target-based Actions, CFTR modulator Indications, Cystic fibrosis CS-0044588 UNII-RZ7027HK8F RZ7027HK8F Olacaftor (VX-440, VX440) is a next-generation CFTR corrector, shows the potential to enhance the amount of CFTR protein at the cell’s surface and for treatment of …

Fezolinetant, фезолинетант , فيزولينيتانت , 非唑奈坦 ,

It’s only fair to share… Fezolinetant ESN-364 Molecular FormulaC16H15FN6OS Average mass358.393 Da Methanone, [(8R)-5,6-dihydro-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl](4-fluorophenyl)- UNII:83VNE45KXX фезолинетант [Russian] [INN] فيزولينيتانت [Arabic] [INN] 非唑奈坦 [Chinese] [INN] (4-Fluorophenyl)[(8R)-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]methanone 10205 1629229-37-3 [RN] 83VNE45KXX Originator Euroscreen Developer Ogeda Class Pyrazines; Small molecules; Triazoles Mechanism of Action Gonadal steroid hormone modulators; Neurokinin 3 receptor antagonists Phase II Hot flashes; Polycystic ovary syndrome; Uterine leiomyoma Preclinical Weight gain DiscontinuedBenign prostatic hyperplasia; Endometriosis 14 Sep 2018 Ogeda completes …

BMS 986142

It’s only fair to share… BMS-986142 (2S,5R,3S)-6-fluoro-5-(3-(8-fluoro-1-methyl-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)-2-methylphenyl)-2-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-l-methyl-2,4-dioxo-l,2-dihydroquinazolin-3(4H)-yl)-2- methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-lH-carbazole-8- carboxamide Molecular Formula, C32-H30-F2-N4-O4, Molecular Weight, 572.609, RN: 1643368-58-4 UNII: PJX9GH268R Originator Bristol-Myers Squibb Class Anti-inflammatories; Antirheumatics; Small molecules Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors Phase II Rheumatoid arthritis; Sjogren’s syndrome 24 Jun 2018 Biomarkers information updated 07 Jun 2018 Bristol-Myers Squibb completes a phase II trial in Rheumatoid arthritis (Treatment-experienced) in Argentina, Austria, Belgium, …

Daprodustat, ダプロデュスタット

It’s only fair to share… Daprodustat, GSK1278863 ダプロデュスタット CAS 960539-70-2 GSK1278863; GSK 1278863; GSK-1278863; Daprodustat C19H27N3O6 Exact Mass: 393.18999 (1,3-dicyclohexyl-2,4,6-trioxohexahydropyrimidine-5-carbonyl)glycine N-[(l,3-dicyclohexyl-6-hydroxy-2,4-dioxo-l,2,3,4- tetrahydro-5-pyrimidinyl)carbonyl]glycine 2-(1,3-dicyclohexyl-2,4,6-triohexahydropyrimidine-5-carboxamide acetic acid Mechanism of Action: HIF-prolyl hydroxylase inhibitor Indication: anemia, diabetic wounds, and reduction of ischemic complications Development Stage: Phase II Developer:GlaxoSmithKline UNII:JVR38ZM64B ダプロデュスタット Daprodustat C19H27N3O6 : 393.43 [960539-70-2] Daprodustat , also known as …

NASTORAZEPIDE

It’s only fair to share…   Nastorazepide (Z-360) CAS: 209219-38-5 Chemical Formula: C29H36N4O5 Molecular Weight: 520.61994 UNII-R22TMY97SG; 209219-38-5; Phase II, treatment of pancreatic cancer. (R)-3-(3-(5-cyclohexyl-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)ureido)benzoic acid Nastorazepide, also known as Z-360, is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. Z-360 binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation …

Zydus receives approval from USFDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis (PBC)

It’s only fair to share… Zydus receives approval from USFDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis (PBC) Read more: https://goo.gl/eugRnZ #ZydusAnnouncement Zydus receives approval from USFDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis (PBC) Ahmedabad, India, February 23, …